Tailored Cancer Therapy: How Genetic Variation Enhances Drug Effectiveness

Researchers at Uppsala University have uncovered promising findings in the quest for personalized cancer therapies. **By targeting genetic variations in cancer cells**, they found that existing drugs could be more effective for certain patients. The study, published in eBiomedicine, focused on genetic phenomena like *loss of heterozygosity*, where cancer cells lose functional gene copies, highlighting differences crucial for targeted treatments. They identified a liver enzyme gene, CYP2D6, often lost in cancer cells, and tested drug compounds in lab models. **Talazoparib**, an approved drug, showed enhanced effects in liver cancer cells lacking CYP2D6. The implications extend to other cancers like neuroblastoma and ovarian cancer. This approach, by aligning therapies with patients' genetic profiles, aims to advance *precision medicine*, offering more effective treatments. The study, funded by several foundations, is a collaborative effort with researchers from Switzerland and the Chemical Biology Consortium Sweden.